FABP4 was also the top-ranked gene among the 58 genes that allowed distinguishing NAFL-NASH patients from NAFL-Steatosis patients according to the PAM results (+1.79-fold, Supplementary Dataset 2, Fig. 2C). This evidence concerns the gene FABP4 and metabolic dysfunction-associated steatohepatitis.